Pephexia Therapeutics ApS
Private limited companyCVR 41319208FrederiksbergActive
Pephexia Therapeutics ApS is a private limited company, based in Frederiksberg, active in research and experimental development on natural sciences and engineering, founded in 2020. Equity was negative at the end of 2025 (−DKK 19.7m). The company made a loss in both 2024 and 2025, most recently DKK 4.4m.
Key figures · financial year 2025
What has changed
calculated from recorded figures and datesFinancials: 2025 against 2024
- The loss got smaller: from DKK 5.3m to DKK 4.4m (2024 → 2025).
Management and owners, last 24 months
- New in management: Ricki Boye (board member, 27/05/2026).
Registrations, last 24 months
- 20/03/2026: Share capital changed from 66,547 DKK to 71,654 DKK
- 01/01/2025: Industry changed to Research and experimental development on natural sciences and engineering (721000)
- 02/12/2024: Share capital changed from 62,387 DKK to 66,547 DKK
Calculated from the latest two annual reports in sequence and from registrations in CVR. A figure that is missing in either year gives no line, and we derive no figures.
Financial statements
Financial years 2022–2025 · amounts in DKK thousandEquity and net profit
| 2022 | 2023 | 2024 | 2025 | Change | |
|---|---|---|---|---|---|
| Revenue | not stated | not stated | not stated | not stated | – |
| Gross profit | −5,266 | −3,212 | −2,085 | −180 | +91.4% |
| Operating profit (EBIT) | −7,864 | −6,013 | −5,801 | −4,376 | +24.6% |
| Profit before tax | −8,548 | −6,972 | −6,821 | −5,691 | +16.6% |
| Net profit | −6,677 | −5,440 | −5,321 | −4,441 | +16.5% |
| Total assets | 9,746 | 5,251 | 5,894 | 2,016 | −65.8% |
| Equity | −7,146 | −12,586 | −15,307 | −19,747 | −29% |
| Liabilities | 16,893 | 17,837 | 21,200 | 21,764 | +2.7% |
| Cash and cash equivalents | 6,647 | 2,613 | 3,844 | 292 | −92.4% |
| Average number of employees | 3 | 3 | 4 | 4 | 0% |
Source: annual reports filed with the Danish Business Authority (XBRL). Figures for the company (not the group); change is the latest year against the year before. “–” means the figure is not stated in the annual report. Revenue is not stated for 2022, 2023, 2024, 2025: smaller companies may omit it, and we do not derive it from other figures.
Download the figures as CSV · free with an account, amounts in whole DKK
Signals from the financial statements
calculated from the 2025 figuresNegative equity
Equity was −DKK 19.7m at the end of 2025.
How is this calculated?
Equity in the latest annual report is below zero.
Loss for 4 years in a row
Net result has been negative in 2022–2025.
How is this calculated?
Net result is negative in the two or more latest annual reports in a row.
The signals are rules applied to the figures in the annual reports. They are not an assessment or credit rating of the company. See Data and method.
Annual reports
4 financial years| Financial year | Period | Published | Figures for | Documents |
|---|---|---|---|---|
| 2025 | 01/01/2025 – 31/12/2025 | 01/06/2026 | The company | PDF not statedXBRL |
| 2024 | 01/01/2024 – 31/12/2024 | 22/04/2025 | The company | PDFXBRL |
| 2023 | 01/01/2023 – 31/12/2023 | 24/05/2024 | The company | PDFXBRL |
| 2022 | 01/01/2022 – 31/12/2022 | 22/05/2023 | The company | PDFXBRL |
The figures from all the annual reports are shown on this page. The documents themselves (PDF and XBRL, the machine-readable edition) are downloaded with a Pro account: sign in or create a free account, and then choose Pro. XBRL is the edition the figures on the page are read from.
Employees
monthly figures from CVRPosition in the industry
431 companies in the databaseComparison with the other companies in research and experimental development on natural sciences and engineering based on the latest financial year.
Industry median: gross profit DKK 616k, net profit −DKK 892k, equity DKK 2m, 5 employees.
Compared with similar companies
size, age and company form| Group | Gross profit | Equity |
|---|---|---|
| Companies with fewer than 20 employees69,967 companies in the comparison | No. 66,744of 69,742 Better than 4% | No. 69,781of 69,964 Better than 0% |
| Same industry and fewer than 20 employees329 companies in the comparison | No. 200of 323 Better than 38% | No. 321of 329 Better than 2% |
| Companies that are between 5 and 14 years old33,688 companies in the comparison | No. 32,478of 33,588 Better than 3% | No. 33,513of 33,687 Better than 1% |
| All companies of type ApS66,508 companies in the comparison | No. 64,000of 66,379 Better than 4% | No. 66,323of 66,505 Better than 0% |
The rank is calculated among companies in the database with a figure for the latest financial year, and is shown only for groups of at least ten companies.
Compare with the industry
Research and experimental development on natural sciences and engineering- Pephexia Therapeutics ApS−DKK 180k
- Carlsberg A/SDKK 40.2bn
- Zealand Pharma A/SDKK 9.2bn
- Pephexia Therapeutics ApS−DKK 4.4m
- Carlsberg A/SDKK 7bn
- Zealand Pharma A/SDKK 6.5bn
- Pephexia Therapeutics ApS−DKK 19.7m
- Carlsberg A/SDKK 30.7bn
- Zealand Pharma A/SDKK 14.8bn
- Pephexia Therapeutics ApS5
- Carlsberg A/S107
- Zealand Pharma A/S569
Latest financial year per company. Choose up to three companies from the largest in the industry.
Owners and group
from the Public Ownership Register- Andrew Justin Stewart Coats5%
- Fogtmann Fosgerau Holding ApS50%
Management
7 active registrationsExecutive management
| Name | Role | Appointed |
|---|---|---|
| Keld Fogtmann Fosgerau | Director | 24/04/2020 |
Board of directors
| Name | Role | Appointed |
|---|---|---|
| Mats Peter Blom | Board member | 02/11/2020 |
| Andrew Justin Stewart Coats | Board member | 02/11/2020 |
| Keld Fogtmann Fosgerau | Board member | 07/07/2022 |
| Anders Mørkeberg Hinsby | Chair of the board | 07/07/2022 |
| Stefan Dietmar Anker | Board member | 22/05/2024 |
| Ricki Boye | Board member | 27/05/2026 |
- Founders
- Fogtmann Fosgerau Holding ApS
Former management (2)
| Name | Role | Appointed | Resigned |
|---|---|---|---|
| Keld Fogtmann Fosgerau | Chair of the board | 02/11/2020 | 06/07/2022 |
| Yann Albert André Colardelle | Board member | 02/11/2020 | 22/05/2024 |
Signing rule: Virksomheden tegnes af en direktør i forening med et bestyrelsesmedlem.
Address and production units
1 active production unitsNordre Fasanvej 215
2000 Frederiksberg
| Production unit | Address | Employees | P number |
|---|---|---|---|
| Pephexia Therapeutics ApS | Nordre Fasanvej 215, 4, 2000 Frederiksberg | 5 | 1025771482 |
Purpose
Virksomhedens formål er forskning og udvikling af lægemidler samt anden dermed beslægtet virksomhed efter direktionens skøn.
The purpose is quoted from the register in Danish.
Changes year by year
31 registered events20263 changesaccounts 1 · management 1 · capital 1
- AccountsAnnual report for 2025 published
- ManagementRicki Boye appointed board member
- CapitalShare capital changed from 66,547 DKK to 71,654 DKK
20252 changesaccounts 1 · industry 1
- AccountsAnnual report for 2024 published
- IndustryIndustry changed to Research and experimental development on natural sciences and engineering (721000)
20245 changescapital 1 · accounts 1 · management 2 · address 1
- CapitalShare capital changed from 62,387 DKK to 66,547 DKK
- AccountsAnnual report for 2023 published
- ManagementStefan Dietmar Anker appointed board member
- ManagementYann Albert André Colardelle stepped down as board member
- AddressMoved to Nordre Fasanvej 215, 4, 2000 Frederiksberg
20231 changeaccounts 1
- AccountsAnnual report for 2022 published
20226 changescapital 1 · ownership 2 · management 3
- CapitalShare capital changed from 58,570 DKK to 62,387 DKK
- OwnershipFogtmann Fosgerau Holding ApS registered as owner (50%)
- OwnershipFogtmann Fosgerau Holding ApS is no longer registered as owner
- ManagementKeld Fogtmann Fosgerau appointed board member
- ManagementAnders Mørkeberg Hinsby appointed chair of the board
- ManagementKeld Fogtmann Fosgerau stepped down as chair of the board
20213 changesaddress 1 · capital 2
- AddressMoved to Ole Maaløes Vej 3, 3, 2200 København N
- CapitalShare capital changed from 54,900 DKK to 58,570 DKK
- CapitalShare capital changed from 52,286 DKK to 54,900 DKK
202011 changescapital 1 · management 5 · ownership 4 · founded 1
- CapitalShare capital changed from 40,000 DKK to 52,286 DKK
- ManagementAndrew Justin Stewart Coats appointed board member
- ManagementYann Albert André Colardelle appointed board member
- ManagementMats Peter Blom appointed board member
- ManagementKeld Fogtmann Fosgerau appointed chair of the board
- OwnershipFogtmann Fosgerau Holding ApS registered as owner (66.67%)
- OwnershipAndrew Justin Stewart Coats registered as owner (5%)
- OwnershipFogtmann Fosgerau Holding ApS is no longer registered as owner
- FoundedRegistered as Pephexia Therapeutics ApS
- ManagementKeld Fogtmann Fosgerau appointed director
- OwnershipFogtmann Fosgerau Holding ApS registered as owner (100%)
Related companies
Same industry in Frederiksberg
- Adcendo ApS49 employees
- Orbis Medicines ApS32 employees
- Minervax ApS28 employees
- Inprother ApS18 employees
- Acesion Pharma ApS16 employees
- Kost Studio ApS11 employees
Same people in management
- Minerva Imaging ApSvia Ricki Boye
- NJORD Law Firm Advokatpartnerselskabvia Ricki Boye
- Icm A/Svia Ricki Boye
- MGS Design & Development A/Svia Ricki Boye
- ZS Associates A/Svia Anders Mørkeberg Hinsby
- Mofibo Books ApSvia Ricki Boye
Largest in the industry
- Carlsberg A/SDKK 40.2bn
- Zealand Pharma A/SDKK 9.2bn
- Gubra A/SDKK 2.6bn
- Vestas Wind Systems A/SDKK 2.5bn
- Bang & Olufsen A/SDKK 1.4bn
- 3shape A/SDKK 1.3bn
Source and updates
The information comes from the Danish Central Business Register (Danish Business Authority) and from annual reports filed with the Danish Business Authority. Last synchronised 24/10/2026. The company is protected against advertising; contact details are not shown, and the data must not be used for marketing.